Loading
Measure the radiation each patient's tumour and kidneys actually absorb and adjust the number and size of doses, instead of giving everyone four identical cycles.
The idea is to personalise peptide receptor radionuclide therapy with lutetium-177 dotatate or 177Lu-edotreotide by measuring the radiation each patient's tumour, kidneys and marrow actually absorb on SPECT/CT after each cycle, and adjusting the number and size of doses. The standard of 7.4 GBq for four cycles leaves many patients under-dosed relative to renal and marrow limits, uptake varies widely, and retrospective dosimetry shows tumour absorbed dose correlates with response. The hypothesis is that dosimetry-guided PRRT raises cumulative tumour dose and response rate without exceeding organ limits. The test is a randomised phase 2 of individualised versus fixed activity; P-PRRT in Canada is already testing this, and the idea addresses the wrong-doses bottleneck.
Shares COMPETE, Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE, Peptide receptor radionuclide therapy (PRRT), Small intestinal neuroendocrine tumours.
Shares Dosimetry, Grade 3 well-differentiated neuroendocrine tumour, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate.
Shares 177Lu-edotreotide, COMPETE, Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE, Peptide receptor radionuclide therapy (PRRT).
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Neuroendocrine tumours.
Shares Dosimetry, Grade 3 well-differentiated neuroendocrine tumour, Lutetium-177 dotatate, Small intestinal neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Lutetium-177 dotatate, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE, Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.